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Abstract
Background: There is a lack of biomarkers to predict outcome with targeted therapy in
metastatic clear cell renal cancer (mccRCC). This may be because dynamic molecular
changes occur with therapy.
Objective: To explore if dynamic, targeted-therapy-driven molecular changes correlate
with mccRCC outcome.
Design, setting, and participants: Multiple frozen samples from primary tumours were
taken from sunitinib-naı¨ve (n = 22) and sunitinib-treated mccRCC patients (n = 23)
for protein analysis. A cohort (n = 86) of paired, untreated and sunitinib/pazopanib-
treated mccRCC samples was used for validation. Array comparative genomic
hybridisation (CGH) analysis and RNA interference (RNAi) was used to support the
ﬁndings.
Intervention: Three cycles of sunitinib 50 mg (4 wk on, 2 wk off).
Outcome measurements and statistical analysis: Reverse phase protein arrays (training
set) and immunoﬂuorescence automated quantitative analysis (validation set) assessed
protein expression.
Results and limitations: Differential expression between sunitinib-naı¨ve and treated
samples was seen in 30 of 55 proteins (p < 0.05 for each). The proteins B-cell CLL/
lymphoma 2 (BCL2), mutL homolog 1 (MLH1), carbonic anhydrase 9 (CA9), and mecha-
nistic target of rapamycin (mTOR) (serine/threonine kinase) had both increased intra-
tumoural variance and signiﬁcant differential expression with therapy. The validation
cohort conﬁrmed increased CA9 expression with therapy. Multivariate analysis showed
high CA9 expression after treatment was associated with longer survival (hazard ratio:
0.48; 95% conﬁdence interval, 0.26–0.87; p = 0.02). Array CGH proﬁles revealed sunitiniby Currently afﬁliated with t
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was associated with signiﬁcant CA9 region loss. RNAi CA9 silencing in two cell lines
inhibited the antiproliferative effects of sunitinib. Shortcomings of the study include
selection of a speciﬁc protein for analysis, and the speciﬁc time points at which the
treated tissue was analysed.
Conclusions: CA9 levels increase with targeted therapy in mccRCC. Lower CA9 levels are
associated with a poor prognosis and possible resistance, as indicated by the validation
cohort.
Patient summary: Drug treatment of advanced kidney cancer alters molecular markers
of treatment resistance. Measuring carbonic anhydrase 9 levels may be helpful in
determining which patients beneﬁt from therapy.
# 2014 European Association of Urology. Published by Elsevier B.V.
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Vascular endothelial growth factor (VEGF)-targeted tyro-
sine kinase inhibitor (TKI) therapy is established as first-line
therapy in metastatic clear cell renal cancer (mccRCC) [1].
Clinical benefit with sunitinib varies among mccRCC
patients. While there are a number of prognostic clinical
factors, there are presently few validated molecular means
of improving prognosis or prediction of response of mccRCC
patients to targeted therapies [2]; the 2012 report of serum
interleukin-6 predicting response to pazopanib is an
exception [3]. This lack of predictive ability is in contrast
to numerous other tumour types, such as chronic myeloid
leukaemia and breast cancer, in which protein expression
and mutation analysis can be used to predict response and
treatment failure [4,5].
Analysis of molecular markers from single tumour
tissue samples taken at baseline in mccRCC has failed to
identify predictive biomarkers associated with response to
sunitinib [6]. We hypothesise that dynamic changes occur
to biomarker expression with VEGF-targeted therapy, and
only tissue taken later in the course of treatment can
predict drug activity. Therefore, by analysing protein
expression from VEGF-treated and untreated renal cancer
tissue, it may be possible to identify and validate protein
biomarkers.
In this work, we compared the expression of 55 key
proteins in nephrectomy tumour samples frompatientswith
mccRCC who were treated with sunitinib prior to nephrec-
tomy or were sunitinib-naı¨ve at the time of surgery.
Extensive intratumoural heterogeneity (ITH) has been
demonstrated in mccRCC [7,8]. ITH is likely to hamper
biomarker research. Toaddress ITH in this study, lysateswere
taken for multiple, spatially separate areas of each primary
tumour. We attempted to identify not only biomarkers that
significantly change with VEGF-targeted therapy, but also
those that demonstrated increased protein variance with
therapy. To confirm these findings, a validation cohort was
used, consisting of paired untreated and anti-VEGF TKI-
treated samples (n = 86) taken from previously untreated
mccRCC patients enrolled in three clinical trials. To further
explore the cause and relevance of changes in protein
expression, arraycomparativegenomichybridisation (aCGH)
was used to identify relevant chromosomal changes, while
RNA interference (RNAi) in RCC cell lines addressed the
functional relevance of significant changes.2. Methods
2.1. Cell lines
See the Supplement for cell-line details.
2.2. Patient samples
Fresh frozen primary ccRCC tissue was obtained from the
nephrectomy samples of 22 sunitinib-naı¨ve mccRCC
patients as part of the Scottish Collaboration On Transla-
tional Research into Renal Cell Cancer study (UK Clinical
Research Network identifier: 12229). Tissue was also
obtained from 27 mccRCC patients treated with three
cycles of presurgical sunitinib (18 wk) as part of the
Upfront Sunitinib (SU011248) Therapy Followed by
Surgery in Patients with Metastatic Renal Cancer: a Pilot
Phase II Study (SuMR; ClinicalTrials.gov identifier:
NCT01024205). Tissue from four of these patients was
entirely necrotic, leaving 23 patients with adequate tissue
for analysis (Table 1). These two sample cohorts made up
the test sample set.
A tissuemicroarray (TMA), with the paraffin-embedded
tissue frommatched, pretreatment primary tumour biopsy
tissue and post-treatment nephrectomy tumour tissue
from the same patients (n = 86), was used as a validation
sample set (TMA construction details are shown in the
Supplement). This tissue came from three prospective
studies—the SuMR study, the Phase II Study Investigating
Upfront Pazopanib InMetastatic Renal Cancer Renal Cancer
(Panther) (ClinicalTrial.gov identifier: NCT01512186), and
the Patient Preference Study of Pazopanib Versus Sunitinib
in Advanced or Metastatic Kidney Cancer (ClinicalTrial.gov
identifier: NCT01064310)—and included patients treated
with sunitinib and pazopanib. Patients were followed up
according to standard guidelines with cross sectional
imaging performed every 12 weeks. Outcome data were
recorded. All studies underwent ethics approval prior to
commencement.
Each piece of fresh frozen tumour tissue was mapped
and separated into small pieces (about 1 cm3) from which
lysates were created. A frozen sectionwas performed (M.O.)
on each 1-cm3 piece of tissue to confirm the presence of
viable ccRCC and also for grading. Where possible, we tried
to obtain a minimum of four protein/DNA lysates per
patient.
Table 1 – Patient demographics, pathology details, and clinical outcomes of test and validation patient cohorts from which there was
adequate tumour tissue for molecular analysis
Cohort Test cohort: total Test cohort: sunitinib naive Test cohort: sunitinib treated Validation cohort
Patients, no. 45 22 23 86
Age, yr, median (IQR) * 66.0 (58.9–73.0) 67.7 (59.1–73.3) 63.0 (56.0–73.0) 61 (51.0–66.3)
Male patients, no. (%) * 30 (67) 14 (64) 16 (70) 66 (77)
Fuhrman grade, no. (%) **
I 0 0 0 0
II 14 (31) 4 (18) 10 (43) 32 (37)
III 22 (49) 10 (45) 12 (52) 31 (36)
IV 9 (20) 8 (36) 1 (4) 14 (16)
Missing data 0 0 0 9 (10)
Stage, no. (%) ***
T1 1 (2) 0 1 (4) 9 (10)
T2 6 (13) 2 (9) 4 (17) 21 (24)
T3 33 (73) 20 (91) 13 (57) 37 (43)
T4 5 (11) 0 5 (22) 14 (16)
Missing data 0 0 0 5 (6)
VHL status, no. (%) *
Mutation 32 (71) 17 (77) 15 (65) NA
Wild type 13 (29) 5 (23) 8 (35)
Metastatic sites, no. (%) *
1 21 (47) 13 (59) 8 (35) 28 (32)
2 18 (40) 7 (32) 11 (48) 34 (40)
3 6 (13) 2 (9) 4 (17) 24 (28)
Heng classiﬁcation, no. (%) *
Intermediate 25 (56) 14 (64) 11 (48) 51(59)
Poor 18 (40) 6 (27) 12 (52) 35 (41)
Missing data 2 (4) 2 (9) 0 0
First-line TKI, no. (%) ^ N/A 11 (50) N/A N/A
Overall survival, mo, median (IQR) * 16.0 (9.1–26.1) 12.3 (7.0–20.0) 23.0 (13.6–30.0) 18 (14.7–23)
IQR = interquartile range; VHL = von Hippel-Lindau; NA = not available; TKI = tyrosine kinase inhibitor; N/A = not applicable.
P values comparing sunitinib-naı¨ve and sunitinib-treated patients: *p > 0.05, **p = 0.02; ***p = 0.04.
^ Number of sunitinib-naı¨ve patients who had postnephrectomy TKIs.
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Protein extraction and reverse phase protein array (RPPA)
spotting and protein quantification were performed as
described previously [9,10]. Protein expression levels from
RC124 and human umbilical vein endothelial cell lines were
used as references on each RPPA slide. Batch effects across
the three RPPA slides per marker were mitigated using
ComBat [11] and data were normalised using variable slope
normalisation [12].
RPPA was used to evaluate 58 proteins. These proteins
were relevant in RCC pathogenesis or sunitinib response
and belonged to the following functional groups: cell cycle,
apoptosis, protein kinases, angiogenesis, cell adhesion, PI3K
pathway, epithelial-to-mesenchymal transition, met proto-
oncogene/hepatocyte growth factor and mismatch repair.
There was no signal detected for three of the proteins
(Ki67, FLT3, and phospho-Jak2). As such, 55 proteins were
analysed in this study (antibodies are detailed in Supple-
mental Table 1).
2.4. Automated quantitative analysis of immunofluorescence
Immunofluorescence and automated quantitative analysis
(AQUA) analysis were performed on the validation cohort,
using methods previously described [13,14].
To correct for any bias due to the separation of pre- and
post-treatment samples on unique TMAs, AQUA results for
the matched tissue samples on each TMA were mediannormalised prior to analysis of significance by theWilcoxon
matched-pairs test. X-tile was used for determining the cut-
off for defining high and low protein expression in the
primary tumour [15].
2.5. Array comparative genomic hybridisation
DNA extraction from fresh frozen tissue and formalin-fixed,
paraffin-embedded specimens was carried out using the
DNeasy Blood and Tissue Kit (Qiagen, Manchester, UK)
according to the manufacturer’s instructions. aCGH hybri-
disation and analysis was carried out as described by Gerth-
Kahlert et al. [16], using the Roche NimbleGen 12  135K
whole-genome array (Roche NimbleGen, Madison, WI,
USA).
The CGH-segMNT module of NimbleScan was used for
the analysis, with aminimum segment length of five probes
and an averaging window of 130 kb. NimbleGen arrays
were positionally annotated based on hg19 genomic
coordinates, and log ratio data were preprocessed in R, as
previously described [17]. Briefly, array data were normal-
ised with print tip Loess from the limma package in R to
produce normalised log ratios, filtered to remove outliers
based on 1 mean absolute deviation of each probe from its
immediate genomic neighbours, and smoothed with a
circular binary segmentation algorithm from the DNACopy
package. Thresholds for smoothed log ratios were then
determined for gain/loss (0.1) and amplification/deletion
(0.45) to identify contiguous copy number aberrations
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aCGH analysis are given in the Supplement.
2.6. RNA interference experiments
The human RCC cell lines CAKI-2 (wild-type von Hippel-
Lindau [VHL]) and RCC11 (a VHL mutant) were transfected
[(Fig._1)TD$FIG]
Fig. 1 – Reverse phase protein array (RPPA) differential protein expression resu
proteins evaluated by RPPA in sunitinib-naı¨ve (light orange) and treated (dark
**p < 0.01, ***p < 0.001.with a nontargeting, control, short interfering RNA
(siRNA) (50-CATGCCTGATCCGCTAGTC-30) or carbonic
anhydrase 9 (CA9) siRNA (50-GAGGAGGATCTGCCCAGT-
GAA-30) (Qiagen,Manchester, UK). Twenty-four hours after
transfection, cells were treated with either 0.01% dimethyl
sulfoxide or 4 mM sunitinib and cell viability was assessed
after 5 d using the Cell Titer Glo assay (Promega,lts. Box-and-whisker plot showing differential expression analysis of 55
orange) metastatic clear cell renal cell carcinoma samples. *p < 0.05,
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Fig. 2 – Results for significantly variable and differentially expressed
proteins in test and validation samples from sunitinib-naı¨ve and
treated patients. (a) Box-and-whisker plot showing test set reverse
phase protein array differential expression results of four key proteins.
Medians and interquartile ranges are shown. (b) Box-and-whisker plot
showing automated quantitative analysis (AQUA) evaluated protein
expression of four key proteins using a validation cohort of 61
sunitinib-treated and 25 pazopanib-treated and untreated paired
metastatic clear cell renal cell carcinoma samples. Of the four proteins,
carbonic anhydrase 9 (CA9) was the only one with significant
differential protein expression (p = 0.01). Medians and interquartile
ranges are shown. (c) Kaplan-Meier curve showing relationship of CA9
protein expression determined by AQUA in situ analysis (low vs high, as
determined using X-tile [15]) in sunitinib/pazopanib-treated patients to
overall survival (hazard ratio: 0.260; 95% confidence interval, 0.111–
0.608; p = 0.001).
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methodology.
2.7. Statistical analysis
Differential expression was assessed per protein between
sunitinib-treated and sunitinib-naı¨ve tumours by applica-
tion of the t test where normality and homoscedasticity
assumptions were satisfied; otherwise, the nonparametric
Mann-WhitneyU testwas used. The F testwas used to assess
intratumoural variances within an analysis of variance
framework for those proteins for which assumptions of
normality and homoscedasticity (within group) were met.
Appropriate false-discovery rate correction was applied to
all p values [18]. Further details on the assessment of
intratumoural variance are given in the Supplement.
Overall survival was estimated using Kaplan-Meier
methods, with differences assessed using the log-rank test.
Multivariate analysis was performed using Cox regression.
SPSS v.20 (IBMCorp, Armonk, NY, USA) or Rwere used for all
statistical analyses.
3. Results
3.1. Patient demographics
Thekeypatient characteristics and treatmentoutcomeswere
comparable for patients in the test set who were not treated
with sunitinib prior to a cytoreductive nephrectomy and
those patients who had sunitinib therapy prior to nephrec-
tomy (Table 1). Of the 45 patients included, 44 had multiple
samples taken (median: 4 regions; range: 2–10 regions).
3.2. Effect of sunitinib treatment on protein expression assessed
by reverse phase protein array
There were significant differences in protein expression
between the treated and untreated samples for 30 of the
55proteinsevaluated in the test set (Fig. 1).Ofparticularnote
were four proteins that had both significant differential
expression and significantly increased intratumoural vari-
ance after sunitinib: B-cell CLL/lymphoma 2 (BCL2), mutL
homolog1 (MLH1), CA9, andmechanistic targetof rapamycin
(serine/threonine kinase) (mTOR) (p < 0.05 for each)
(Fig. 2a).
3.3. Automated quantitative analysis results from the
validation cohort
BCL2, MLH1, CA9, and mTOR protein expression was
evaluated using in situ staining and AQUA of the validation
TMA (paired treated and untreated samples from the same
patient [n = 86]). This analysis revealed that of these four
proteins, only CA9was significantly differentially expressed
(increased) with treatment ( p = 0.01) (Fig. 2b). High
expression of CA9 in sunitinib-treated tissue was associated
with good overall survival (OS) (hazard ratio [HR]: 0.26; 95%
confidence interval [CI], 0.11–0.61; log rank test p = 0.001)
(Fig. 2c). Results from the multivariate analysis, whichincluded a number of prognostic factors (ie, Heng prognos-
tic score, Fuhrman grade, T stage at diagnosis, number of
metastatic sites, age, and CA9 expression in nephrectomy
ccRCC specimen) in the model showed that low Fuhrman
[(Fig._3)TD$FIG]
Fig. 3 – Array comparative genomic hybridization and RNA interference carbonic anhydrase 9 (CA9) results. (a) Heat map plotting gains (red) and losses
(blue) of CA9. The right-hand bar represents the logarithm of the odds score (Slog10) of the adjusted p value (Fisher test), the dashed line represents
p = 0.05. There were significantly more losses in the treated samples relative to the untreated patient samples (p = 0.002). Supplemental Figure 1
provides further description of regional chromosomal changes and Supplemental Figure 2 provides details of the genome-wide changes in gains and
losses following sunitinib therapy. (b) RCC11 and (c) CAKI-2 human renal cell carcinoma transfected with either control or CA9 short interfering RNA
(siRNA), followed by sunitinib treatment and cell viability analysis 5 d later. Error bars represent standard errors of the mean. To confirm silencing,
cell lysates from RCC11 and CAKI-2 siRNA transfected cells were analysed by western blotting using CA9 and b-actin-specific antibodies, as indicated.
VHL = von Hippel-Lindau; Del = deletion; mut = mutant; NC = no change; wt = wild-type.
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at nephrectomy (HR: 0.48; 95% CI, 0.26–0.87), were
associated with a good OS. Full results are reported in
Supplemental Table 2.
3.4. Array comparative genomic hybridisation analysis
DNA from the test set of samples from sunitinib-naı¨ve and
sunitinib-treated patients was used for aCGH analysis to
compare chromosomal aberrations. The total number of
aberrations was significantly greater in treated samples.
Comparisons of gains, losses, amplifications, and deletions in
sunitinib-treated and untreated samples revealed signifi-
cantly greater levels of chromosomal losses in the region
encoding CA9 in the treated samples (Fisher test p = 0.002)
(Fig. 3a). Conversely, the increase in losses across the whole
genome was not significant (Supplemental Fig. 2).
3.5. Functional analysis of CA9 using RNA interference in renal
cancer cell lines
Results fromboth renal cancer cell lines (CAKI-2 and RCC11)
showed CA9 was successfully silenced with siRNA (Fig. 3b
and 3c). The cell viability assay showed CA9 silencing
inhibited the antiproliferative effects of sunitinib, regard-
less of cell-line VHL status. These results support the
findings from the clinical tissue, where low levels of CA9
were associated with poor outcome from sunitinib therapy.
4. Discussion
In this work, we have demonstrated that VEGF-targeted
therapy significantly alters the expression of a number of
selected proteins despite protein ITH.Four proteins—CA9, MLH1, mTOR, and BCL2—showed
both significant changes in expression and increases
intratumoural variance with sunitinib. These dynamically
variable and changing proteins were chosen for further
evaluation due to the likelihood of them being biologically
relevant. Of these four proteins, CA9 upregulation revealed
significant results in the validation cohort and functional
cell-line work.
CA9 is a hypoxia-regulated transmembrane protein
overexpressed in a number of cancers. It is usually
associated with hypoxic stress and poor prognosis [19].
Extensive investigation has been performed in renal cancer,
due to the frequency of CA9 overexpression and conflicting
results regarding its prognostic value [19–21]. CA9 is
overexpressed in the vast majority of ccRCC and has
promise at a diagnostic level [20]; but paradoxically, high
CA9 levels correlate with good outcomes in some studies
[21]. Tumour samples in the pre-VEGF TKI era showed
conflicting data on the prognostic value of baseline CA9
[21,22]. Prospective studies showed CA9 was not able to
predict response to immune therapy [23]. Together, these
data suggested that CA9 did not have a crucial predictive
role in the era of immune therapy.
Biomarker studies in the era of VEGF-targeted therapy
have failed to consistently show that high baseline CA9
protein levels are associated with a good outcome [24,25].
This may be because of the dynamic changes that occur with
therapy and theuse of archival tissue froma single timepoint
for biomarker analysis. The work presented here shows that
not only does targeted therapy increase the expression of
CA9, but these changing levels are also prognostic. These
findings were observed in both interpatient (unmatched test
set) and, critically, the intrapatient (matched sequential
biopsy and nephrectomy validation set) samples.
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 9 5 6 – 9 6 3962This dynamic change in a prognostically important
biomarker suggests the drive towards predictive biomark-
ers may be possible. Anti-VEGF therapy is associated with
vasoconstriction and subsequent hypoxia [8]; therefore, the
upregulation of CA9 with VEGF-targeted therapy could be a
consequence of effective VEGF targeting. Indeed, Figure 1
shows that a number of VEGF- and hypoxia-associated
markers are also affected by sunitinib (eg, VEGF receptor
[VEGFR]-1, VEGFR-3, platelet-derived growth factor recep-
tor-b, c-KIT, VEGF-A, VEGF-D), supporting this argument. Of
note, hypoxia-inducible factor 1a was not differentially
expressed, most likely due to its short half-life, which was
exceeded by the warm ischaemia time during sample
acquisition.
Alternatively, CA9 may have more of a direct oncogenic
effect as a reaction to VEGF-targeted therapy. The silencing
of CA9 in renal cancer cell lines resulted in inhibition of the
antiproliferative effects of sunitinib. While not conclusive,
these in vitro findings support our clinical sample data.
Together, these results suggest a role for CA9 in sunitinib
activity and that CA9 may be relevant in the development
of sunitinib resistance. Previous studies have shown that
CA9 can affect cell adhesion and contact inhibition,
demonstrating a role beyond simply a reaction to hypoxia
[26,27]. The work presented here also shows that sunitinib
treatment is associatedwith chromosomal changes to CA9.
These chromosomal changes also point to a change in
tumour DNA rather than simply a stromal reaction to
hypoxia.
A biomarker identified after a specific period of therapy
is of potential clinical use, providing patients are willing to
have a repeated biopsy during treatment. The utility of
repeated biopsy in practice is challenging. A randomised
trial comparing continued therapy with a change in therapy
in those patients who failed to gain a rise in CA9 level with
therapy would test this biomarker prospectively.
There are several strengths to this work. Obtaining
sequential tissue in metastatic renal cancer is challenging
and this is, to our knowledge, the largest series available.
Different techniques to measure protein expression were
used in the training and validation set; furthermore, the
chromosomal and in vitro work support the CA9 findings.
However, there are a number of limitations of this study.
First, the 55 proteins chosen for analysis may be subject to
selection bias. Also, the initial biomarker testing was not
performed in matched pairs from the same individual.
Ideally, RPPA and aCGH would have been performed using
matched samples from the same patient before and after
sunitinib therapy; this was not feasible due to the amount
of fresh frozen tumour tissue required to allow multilevel
molecular analysis frommultiple, spatially variant regions
of the same tumours. However, the characteristics of the
two test-set groups were similar and validation of the
biomarkers occurred in paraffin-embeddedmatched pairs.
Biomarker analysis took place at a specific time point with
therapy and following a 2-wk break before nephrectomy,
which may have influenced biomarker expression. Finally,
the in vitro study does not assess the effect of sunitinib on
the tumour vasculature [28], the main target of thistreatment,which is a limitation of the epithelial cell culture
used in this study.
5. Conclusions
This study illustrates the dynamic changes to relevant
proteins with anti-VEGF targeted therapies. Despite these
dynamic changes and factoring in ITH, it was possible to
identify and validate CA9 as an independent predictor of
outcome following anti-VEGF targeted therapy. There were
consistent dynamic changes to CA9 at chromosomal and
protein levels. Together with the multivariate analysis and
in vitro studies, these results suggest CA9 may have
relevance to sunitinib resistance. CA9 modulation to
overcome anti-VEGF therapy resistance may be a potential
therapeutic area of investigation in the future.
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